A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
• Advanced non-small cell lung cancer
• Adequate organ and marrow function
• Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Rachel Sanborn, M.D.
- Oncology and Hematology Care Eastside